Self-facilitated ROS-responsive nanoassembly of heterotypic dimer for synergistic chemo-photodynamic therapy

Luo, Cong; Sun, Bingjun; Wang, Chen; Zhang, Xuanbo; Chen, Yao; Chen, Qin; Ye, Han; Zhao, Hanqing; Sun, Mengchi; Li, Zhenbao; Zhang, Haotian; Kan, Qiming; Wang, Yongjun; Zhang, He; Sun, Jin

doi:10.1016/j.jconrel.2019.04.001

Cited by 132 publications

(76 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this repetitive and sequential process -the induction of caspase-3 and activation of the prodrug- propagated the induction of apoptosis and amplified therapeutic effects 70, 71. Similar to the mechanism of enzyme-responsive nanomedicine, glutathione disulfide has been utilized for developing reduction-responsive nanomedicine 72, 73.…”

Section: Utilization Of Tme-specific Molecular Markersmentioning

confidence: 99%

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

et al. 2019

View full text Add to dashboard Cite

The use of nanomedicine for cancer treatment takes advantage of its preferential accumulation in tumors owing to the enhanced permeability and retention (EPR) effect. The development of cancer nanomedicine has promised highly effective treatment options unprecedented by standard therapeutics. However, the therapeutic efficacy of passively targeted nanomedicine is not always satisfactory because it is largely influenced by the heterogeneity of the intensity of the EPR effect exhibited within a tumor, at different stages of a tumor, and among individual tumors. In addition, limited data on EPR effectiveness in human hinders further clinical translation of nanomedicine. This unsatisfactory therapeutic outcome in mice and humans necessitates novel approaches to improve the EPR effect. This review focuses on current attempts at overcoming the limitations of traditional EPR-dependent nanomedicine by incorporating supplementary strategies, such as additional molecular targeting, physical alteration, or physiological remodeling of the tumor microenvironment. This review will provide valuable insight to researchers who seek to overcome the limitations of relying on the EPR effect alone in cancer nanomedicine and go “beyond the EPR effect”.

show abstract

Section: Utilization Of Tme-specific Molecular Markersmentioning

confidence: 99%

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The therapeutic efficacy of single drug is far from satisfactory due to the limited antitumor effect of one drug, drug resistance and tumor heterogeneity (Luo et al 2019). Particularly, the anticancer activity of MET depends on regulation of the cellular metabolic pathways (Wang et al 2017;Shurrab and Arafa 2020).…”

Section: Nano-dds Of Met For Combination Cancer Therapymentioning

confidence: 99%

Emerging nanoparticulate drug delivery systems of metformin

Chen

Shan

Luo

et al. 2020

J. Pharm. Investig.

Self Cite

View full text Add to dashboard Cite

Background Driving the conventional drug in new applications has emerged as a research hotspot for disease treatment. Metformin (MET) is conventionally used for the treatment of type II diabetes. It has also been found to be a versatile molecule with wide biological functions, such as losing weight. anti-aging and anticancer activity. Rational design of nanoparticulate drug delivery systems (nano-DDS) could significantly improve drug delivery efficiency. Recently, a wide range of nano-DDS has been developed to improve the delivery efficacy of MET or to perform as versatile nanoplatforms for efficient drug delivery. Area covered In this review, we outline the emerging trends in advanced nano-DDS of MET, focusing on nano-DDS of MET for diabetes therapy, nano-DDS of MET for anticancer therapeutics, and nano-DDS of MET for other therapeutic aims. Expert opinion Despite the great progression in nano-DDS of MET, there's still a long way to truly put the conventional drug in new applications. Several important issues should be fully taken into consideration, such the manufacturing cost and economic burdens for patients, the biocompatibility and long-term toxicity of carrier materials, scale-up preparation difficulties, as well as the species gap between human beings and animal models.

show abstract

“…[133] Recently, several studies have revealed that the aggregationcaused quenching (ACQ) effect of PS impairs the therapeutic efficacy of PDT by suppressing ROS generation. [16,135] To minimize this ACQ effect, extensive efforts have aimed to develop a tumor microenvironment-responsive PS prodrug. The PS prodrug forms aggregates in the systemic circulation, which helps reduce phototoxicity before reaching the tumor site.…”

Section: Binary Cooperative Prodrug Nanomedicines For Improved Cancermentioning

confidence: 99%

Engineering Prodrug Nanomedicine for Cancer Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Immunotherapy has shifted the clinical paradigm of cancer management. However, despite promising initial progress, immunotherapeutic approaches to cancer still suffer from relatively low response rates and the possibility of severe side effects, likely due to the low inherent immunogenicity of tumor cells, the immunosuppressive tumor microenvironment, and significant interand intratumoral heterogeneity. Recently, nanoformulations of prodrugs have been explored as a means to enhance cancer immunotherapy by simultaneously eliciting antitumor immune responses and reversing local immunosuppression. Prodrug nanomedicines, which integrate engineering advances in chemistry, oncoimmunology, and material science, are rationally designed through chemically modifying small molecule drugs, peptides, or antibodies to yield increased bioavailability and spatiotemporal control of drug release and activation at the target sites. Such strategies can help reduce adverse effects and enable codelivery of multiple immune modulators to yield synergistic cancer immunotherapy. In this review article, recent advances and translational challenges facing prodrug nanomedicines for cancer immunotherapy are overviewed. Last, key considerations are outlined for future efforts to advance prodrug nanomedicines aimed to improve antitumor immune responses and combat immune tolerogenic microenvironments.

show abstract

Self-facilitated ROS-responsive nanoassembly of heterotypic dimer for synergistic chemo-photodynamic therapy

Cited by 132 publications

References 23 publications

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

Emerging nanoparticulate drug delivery systems of metformin

Engineering Prodrug Nanomedicine for Cancer Immunotherapy

Contact Info

Product

Resources

About